Agios Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2008-01-01
- Employees
- 386
- Market Cap
- $2.6B
- Website
- http://www.agios.com
- Introduction
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is...
Pyruvate Kinase Deficiency Global Longitudinal Registry Substudy of Protocol AG348-C-008
- Conditions
- First Posted Date
- 2021-08-06
- Last Posted Date
- 2023-10-16
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT04995315
- Locations
- 🇳🇱
Universitair Medisch Centrum Utrecht, Utrecht, Netherlands
🇮🇹Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Pyruvate Kinase (PK) Deficiency Global Longitudinal Registry: Patient-Reported Outcomes (PRO)
- First Posted Date
- 2021-07-16
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT04964323
- Locations
- 🇳🇱
Universitair Medisch Centrum Utrecht, Utrecht, Netherlands
🇮🇹Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)
- Conditions
- Interventions
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 258
- Registration Number
- NCT04770779
- Locations
- 🇺🇸
Penn Medicine - University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States
🇺🇸Phoenix Children's Hospital, Phoenix, Arizona, United States
🇮🇹Ospedale Pediatrico Microcitemico, Cagliari, Italy
A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)
- Conditions
- Interventions
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 194
- Registration Number
- NCT04770753
- Locations
- 🇧🇬
UMHAT "Sveti Georgi" EAD, Plovdiv, Bulgaria
🇧🇬SHATHD Sofia, Sofia, Bulgaria
🇬🇷Children's Hospital Agia Sophia, National and Kapodistrian University of Athens Medical School, Athens, Greece
A Study to Compare the Pharmacokinetics and Safety of Mitapivat 100 mg Tablet Formulation With Mitapivat 2 × 50 mg Tablet Formulation in Healthy Adult Participants
- First Posted Date
- 2021-01-06
- Last Posted Date
- 2021-04-13
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT04696393
- Locations
- 🇺🇸
PPD Development, LP, Austin, Texas, United States
A Study to Assess the Relative Bioavailability and Effect of Food on the Coated Granule Formulation of Mitapivat in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2020-09-25
- Last Posted Date
- 2020-12-10
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT04565678
- Locations
- 🇺🇸
Covance Clinical Research Unit Inc., Dallas, Texas, United States
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With Sickle Cell Disease
- Conditions
- Interventions
- First Posted Date
- 2020-09-03
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 122
- Registration Number
- NCT04536792
- Locations
- 🇪🇸
Hospital Universitario Vall d'Hebron - PPDS, Barcelona, Spain
🇺🇸Texas Oncology-Baylor Charles A. Sammons Cancer Center - USOR, Dallas, Texas, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Mitapivat (AG-348) in Healthy Adult Participants
- Conditions
- Interventions
- First Posted Date
- 2020-07-15
- Last Posted Date
- 2021-02-18
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT04472832
- Locations
- 🇺🇸
PPD Development, LP, Austin, Texas, United States
A Study to Evaluate AG-881 in Healthy Japanese and Non-Asian Participants
- First Posted Date
- 2019-10-30
- Last Posted Date
- 2020-04-02
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT04145128
- Locations
- 🇺🇸
WCCT GLobal, Cypress, California, United States
A Study to Compare the Relative Bioavailability of Two AG-881 Formulations and Evaluate the Effect of Food and Omeprazole on the Pharmacokinetics of AG-881
- Conditions
- Interventions
- First Posted Date
- 2019-10-16
- Last Posted Date
- 2021-07-21
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT04128787
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States